Concepedia

Kate S. Ashton

KS

Statistics

Publications

14

Citations

1.1K

H-Index

12

Active since

2003

Affiliations

Amgen (United States)(Current)

Syngene International (India)

Kate S. Ashton is an author at Amgen (United States) specializing in drug discovery, medicinal chemistry, and pharmacology.

Publications per year

2003–2025

14

Publications

14

Discovery of a Covalent Inhibitor of KRAS<sup>G12C</sup> (AMG 510) for the Treatment of Solid Tumors

Brian A. Lanman, Jennifer R. Allen, John G. Allen et al. · Journal of Medicinal Chemistry · 2019 · 722 citations · Full text

, , +16

Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors

David J. Lloyd, David J. St. Jean, Robert J. Kurzeja et al. · Nature · 2013 · 98 citations

, , +14

Small Molecule Disruptors of the Glucokinase–Glucokinase Regulatory Protein Interaction: 3. Structure–Activity Relationships within the Aryl Carbinol Region of the <i>N</i>-Arylsulfonamido-<i>N</i>′-arylpiperazine Series

Nobuko Nishimura, Mark H. Norman, Longbin Liu et al. · Journal of Medicinal Chemistry · 2014 · 54 citations · Full text

, , +11

Discovery and Structure-Guided Optimization of Diarylmethanesulfonamide Disrupters of Glucokinase–Glucokinase Regulatory Protein (GK–GKRP) Binding: Strategic Use of a N → S (n<sub>N</sub> → σ*<sub>S–X</sub>) Interaction for Conformational Constraint

Lewis D. Pennington, Michael D. Bartberger, Michael D. Croghan et al. · Journal of Medicinal Chemistry · 2015 · 41 citations · Full text

, , +17

Small Molecule Disruptors of the Glucokinase–Glucokinase Regulatory Protein Interaction: 1. Discovery of a Novel Tool Compound for in Vivo Proof-of-Concept

Kate S. Ashton, Kristin L. Andrews, Marion C. Bryan et al. · Journal of Medicinal Chemistry · 2014 · 33 citations · Full text

, , +9

1–5 of 14